Browsing "1. Journal Papers" by Author : 834

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:
  • Sort by:
  • In order:
  • Results/Page
  • Authors/Record:

Showing results 41 to 55 of 55

This table browses all dspace content
Issue DateTitleJournal Title
2020Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer SCIENTIFIC REPORTS
2015Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neckCLINICAL CANCER RESEARCH
2015Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma ONCOTARGET
2019PI3K/AKT/β-Catenin Signaling Regulates Vestigial-Like 1 Which Predicts Poor Prognosis and Enhances Malignant Phenotype in Gastric Cancer CANCERS
2013Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
2017Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype ONCOTARGET
2016Prognostic Tests for Estrogen Receptor-Positive Breast Cancer: Need for Global Consideration and Further EvolutionJAMA ONCOLOGY
2015Prospective Validation of a 21-Gene Expression Assay in Breast Cancer NEW ENGLAND JOURNAL OF MEDICINE
2018Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells with Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRTGASTROENTEROLOGY
2019Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast CancerJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
2018Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth GENOME RESEARCH
2017The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40ANNALS OF SURGICAL ONCOLOGY
2018Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology)BRITISH JOURNAL OF CANCER
2019Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trialLANCET ONCOLOGY
2020Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831 JNCI CANCER SPECTRUM
1

Browse

Links